Clinical Scenario

Stage IIB · T3

This protocol addresses patients with Mycosis fungoides at clinical stage IIB, defined by the presence of one or more skin tumours measuring at least 1 cm in diameter (T3 classification). This stage represents locally advanced cutaneous disease.

Treatment Approach

Management at this stage involves systemic therapy, with the appropriate option guided in part by tumour CD30 expression status and individual patient factors. The full protocol specifies the complete range of options, selection criteria, and any restrictions on eligibility.

References

DOI: 10.1016/j.ejca.2023.113343

Recommendations for first-line treatment of MF stage IIB.
Cyclophosphamide Hydroxydaunorubicin (Doxorubicin) Oncovin (Vincristin) Prednisone (CHOP) is the most widely used regimen with a number of variants and other combinations available.
Based on the results of the ALCANZA trial (see below) the drug is approved in Europe for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
The drug is approved in Europe for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.
Apart from the rare situation of local radiotherapy for mono-localised MF (see above) allogeneic stem cell transplantation (alloSCT) is the only option in MF/SS with curative intention in patients with advanced disease.

View source ↗

Treatment of Mycosis Fungoides at Clinical Stage IIB — T3 Disease with One or More Skin Tumours ≥1 cm

Clinical Scenario

Treatment Approach

References